Literature DB >> 26192885

Atrial fibrillation and heart failure: update 2015.

Sudarone Thihalolipavan1, Daniel P Morin2.   

Abstract

Heart failure (HF) and atrial fibrillation (AF) commonly coexist, adversely affect mortality, and impose a significant burden on healthcare resources. The presence of AF and HF portends a poor prognosis as well as an increased thromboembolic risk. In patients whose AF is symptomatic, rhythm restoration with either antiarrhythmic drugs or procedural therapies (e.g., pulmonary vein isolation, either catheter-based or surgical) should be considered for symptom improvement, though a mortality benefit has yet to be demonstrated. Emerging evidence suggests that non-pharmacological treatment for AF (including catheter based ablation, hybrid surgical techniques, and atrioventricular node ablation with biventricular pacing) may be of value in improving HF patients' quality of life.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-arrhythmia drugs; Anticoagulation; Atrial fibrillation; Catheter ablation; Heart failure

Mesh:

Substances:

Year:  2015        PMID: 26192885     DOI: 10.1016/j.pcad.2015.07.004

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  18 in total

1.  Surgical ablation for atrial fibrillation: an editorial.

Authors:  Pouya Nezafati; Mojgan Gharipour; Mohammad Hassan Nezafati
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

2.  Rosuvastatin reduces the recurrence rate following catheter ablation for atrial fibrillation in patients with heart failure.

Authors:  Guojun Zhao; Leiming Wu; Yuzhou Liu; Lu Gao; Yang Chen; Rui Yao; Yanzhou Zhang
Journal:  Biomed Rep       Date:  2017-01-17

Review 3.  Cardiac rhythm disorders in obstructive sleep apnea.

Authors:  Glaucylara Reis Geovanini; Geraldo Lorenzi-Filho
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 4.  Arrhythmogenic mechanisms of obstructive sleep apnea in heart failure patients.

Authors:  Karan R Chadda; Ibrahim T Fazmin; Shiraz Ahmad; Haseeb Valli; Charlotte E Edling; Christopher L-H Huang; Kamalan Jeevaratnam
Journal:  Sleep       Date:  2018-09-01       Impact factor: 5.849

5.  Aging-induced atrial fibrosis in If current change and its effect on atrial fibrillation in dogs.

Authors:  Fei-Fei Wang; Ya-Fan Han; Xiao-Yan Liang; Ge-Ge Zhang; Yan-Mei Lu; Yao-Dong Li; Bao-Peng Tang
Journal:  Ann Noninvasive Electrocardiol       Date:  2022-04-11       Impact factor: 1.485

Review 6.  Evaluating the benefits of home-based management of atrial fibrillation: current perspectives.

Authors:  Azfar B Sheikh; Jamie R Felzer; Abdullah Bin Munir; Daniel P Morin; Carl J Lavie
Journal:  Pragmat Obs Res       Date:  2016-10-13

7.  Comments to "Neutrophil-to-lymphocyte ratio compared to N-terminal pro-brain natriuretic peptide as a prognostic marker of adverse events in elderly patients with chronic heart failure".

Authors:  Kahraman Cosansu; Çağın Mustafa Üreyen
Journal:  J Geriatr Cardiol       Date:  2017-10       Impact factor: 3.327

8.  Neutrophil-to-lymphocyte ratio compared to N-terminal pro-brain natriuretic peptide as a prognostic marker of adverse events in elderly patients with chronic heart failure.

Authors:  Wei Yan; Rui-Jun Li; Qian Jia; Yang Mu; Chun-Lei Liu; Kun-Lun He
Journal:  J Geriatr Cardiol       Date:  2017-02       Impact factor: 3.327

Review 9.  Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times.

Authors:  Syeda Atiqa Batul; Rakesh Gopinathannair
Journal:  Korean Circ J       Date:  2017-08-22       Impact factor: 3.243

10.  Risk factors for heart failure hospitalizations among patients with atrial fibrillation.

Authors:  Lucien Eggimann; Steffen Blum; Stefanie Aeschbacher; Andreas Reusser; Peter Ammann; Paul Erne; Giorgio Moschovitis; Marcello Di Valentino; Dipen Shah; Jürg Schläpfer; Nadine Mondet; Michael Kühne; Christian Sticherling; Stefan Osswald; David Conen
Journal:  PLoS One       Date:  2018-02-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.